<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550209</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-00517</org_study_id>
    <secondary_id>R61AT009632</secondary_id>
    <nct_id>NCT03550209</nct_id>
  </id_info>
  <brief_title>Fatty Acid Supplementation in Children With ASD</brief_title>
  <acronym>Omega Heroes</acronym>
  <official_title>Fatty Acid Supplements Alter Biological Signatures in Children With Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarah Keim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine how fatty acid supplementation alters biological&#xD;
      signatures in children with ASD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with Autism Spectrum Disorder (ASD) suffer from both mental and physical symptoms&#xD;
      that affect their quality of life and severely disrupt family well-being. Fatty acid&#xD;
      supplements are natural products with anti-inflammatory properties often used for treatment&#xD;
      of ASD symptoms, but their efficacy remains unproven. The objective of the proposed protocol&#xD;
      is to quantify the impact of Omega 3-6 on pre-specified biological signatures. The hypotheses&#xD;
      were formulated based on data from the investigators previous studies and other published&#xD;
      data which suggest that the inflammatory markers, IL-1β, IL-2, and IFNγ are consistently&#xD;
      elevated in children with ASD and decreases in these markers correlate with ASD symptom&#xD;
      improvement. The investigators long-term goal is to identify effective treatments for ASD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>Baseline to 90 days post-randomization</time_frame>
    <description>Group differences in bioavailability; each fatty acid as a percent of total erythrocyte fatty acids at the end of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety (Adverse Events)</measure>
    <time_frame>Baseline to 90 days post-randomization</time_frame>
    <description>Average number of adverse events per treatment group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological Signatures</measure>
    <time_frame>Baseline to 90 days post-randomization</time_frame>
    <description>Changes in the biological signatures (IL-1β, IL-2, IFNγ) from baseline to the end of the trial.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>LCPUFA Oil Supplement, Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCPUFA Oil Supplement, Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCPUFA Oil Supplement, High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canola Oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCPUFA Oil Supplement</intervention_name>
    <description>25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
    <arm_group_label>LCPUFA Oil Supplement, High Dose</arm_group_label>
    <arm_group_label>LCPUFA Oil Supplement, Low Dose</arm_group_label>
    <arm_group_label>LCPUFA Oil Supplement, Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Canola Oil Placebo</intervention_name>
    <description>Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
    <arm_group_label>Canola Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 2-6 years old&#xD;
&#xD;
          -  ASD diagnosis at Nationwide Children's Hospital within the prior 6 months&#xD;
&#xD;
          -  ADOS-2 score in &quot;autism&quot; (severe) range&#xD;
&#xD;
          -  English is primary language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fatty acid supplementation in the past 6 months&#xD;
&#xD;
          -  Consumes fatty fish more than 3 times per week&#xD;
&#xD;
          -  Still breastfeeding or formula feeding&#xD;
&#xD;
          -  Quadriparesis&#xD;
&#xD;
          -  Deafness&#xD;
&#xD;
          -  Blindness&#xD;
&#xD;
          -  Seizure disorder diagnosis&#xD;
&#xD;
          -  Autoimmune disorder including Type 1 Diabetes, Fragile X, Rett, Angleman Syndromes,&#xD;
             Tuberous Schlerosis&#xD;
&#xD;
          -  Feeding problems precluding consumption of the supplement&#xD;
&#xD;
          -  Ingredient allergy (canola, fish, or borage seed)&#xD;
&#xD;
          -  Planned surgeries scheduled within the time frame of trial participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Keim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynette Rogers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <results_first_submitted>January 21, 2021</results_first_submitted>
  <results_first_submitted_qc>March 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2021</results_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Sarah Keim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LCPUFA Oil Supplement, Low Dose</title>
          <description>25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="P2">
          <title>LCPUFA Oil Supplement, Medium Dose</title>
          <description>50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="P3">
          <title>LCPUFA Oil Supplement, High Dose</title>
          <description>75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="P4">
          <title>Canola Oil</title>
          <description>Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days&#xD;
Canola Oil Placebo: Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded due to ineligibility after randomization</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>72 participants were randomized into the study, but only 70 participants were included in analysis. Two participants who were randomized to receive canola oil (placebo) were found to be ineligible after randomization. These two participants were unenrolled from the study by the Principal Investigators and were not included in any analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>LCPUFA Oil Supplement, Low Dose</title>
          <description>25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="B2">
          <title>LCPUFA Oil Supplement, Medium Dose</title>
          <description>50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="B3">
          <title>LCPUFA Oil Supplement, High Dose</title>
          <description>75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="B4">
          <title>Canola Oil</title>
          <description>Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days&#xD;
Canola Oil Placebo: Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>2-3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Black or African-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other or Multiple Races</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pre-Specified Biological Signatures (cytokines)</title>
          <description>A blood draw was completed at the first study visit prior to beginning any study interventions. This blood draw was used to collect baseline data for pre-specified biological signatures.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>IL-1β</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.10" spread="0.05"/>
                    <measurement group_id="B2" value="0.16" spread="0.25"/>
                    <measurement group_id="B3" value="0.07" spread="0.05"/>
                    <measurement group_id="B4" value="0.10" spread="0.06"/>
                    <measurement group_id="B5" value="0.11" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.31" spread="0.12"/>
                    <measurement group_id="B2" value="0.55" spread="0.96"/>
                    <measurement group_id="B3" value="0.23" spread="0.10"/>
                    <measurement group_id="B4" value="0.48" spread="0.47"/>
                    <measurement group_id="B5" value="0.39" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNγ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.95" spread="6.40"/>
                    <measurement group_id="B2" value="11.22" spread="10.18"/>
                    <measurement group_id="B3" value="9.80" spread="7.35"/>
                    <measurement group_id="B4" value="16.72" spread="43.17"/>
                    <measurement group_id="B5" value="11.67" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioavailability</title>
        <description>Group differences in bioavailability; each fatty acid as a percent of total erythrocyte fatty acids at the end of the trial</description>
        <time_frame>Baseline to 90 days post-randomization</time_frame>
        <population>11 participants were not included in analysis due to missing a scheduled blood draw at 90 days post randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>LCPUFA Oil Supplement, Low Dose</title>
            <description>25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O2">
            <title>LCPUFA Oil Supplement, Medium Dose</title>
            <description>50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O3">
            <title>LCPUFA Oil Supplement, High Dose</title>
            <description>75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O4">
            <title>Canola Oil</title>
            <description>Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days&#xD;
Canola Oil Placebo: Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Bioavailability</title>
          <description>Group differences in bioavailability; each fatty acid as a percent of total erythrocyte fatty acids at the end of the trial</description>
          <population>11 participants were not included in analysis due to missing a scheduled blood draw at 90 days post randomization.</population>
          <units>mol%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EPA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="1.04"/>
                    <measurement group_id="O2" value="1.80" spread="1.56"/>
                    <measurement group_id="O3" value="3.00" spread="2.45"/>
                    <measurement group_id="O4" value="0.80" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.26"/>
                    <measurement group_id="O2" value="3.61" spread="1.39"/>
                    <measurement group_id="O3" value="4.75" spread="1.76"/>
                    <measurement group_id="O4" value="2.46" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety (Adverse Events)</title>
        <description>Average number of adverse events per treatment group</description>
        <time_frame>Baseline to 90 days post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LCPUFA Oil Supplement, Low Dose</title>
            <description>25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O2">
            <title>LCPUFA Oil Supplement, Medium Dose</title>
            <description>50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O3">
            <title>LCPUFA Oil Supplement, High Dose</title>
            <description>75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O4">
            <title>Canola Oil</title>
            <description>Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days&#xD;
Canola Oil Placebo: Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety (Adverse Events)</title>
          <description>Average number of adverse events per treatment group</description>
          <units>events per person</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="2.35"/>
                    <measurement group_id="O2" value="3.33" spread="2.23"/>
                    <measurement group_id="O3" value="5.62" spread="2.81"/>
                    <measurement group_id="O4" value="3.88" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biological Signatures</title>
        <description>Changes in the biological signatures (IL-1β, IL-2, IFNγ) from baseline to the end of the trial.</description>
        <time_frame>Baseline to 90 days post-randomization</time_frame>
        <population>11 participants were not included in analysis due to missing a scheduled blood draw at 90 days post randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>LCPUFA Oil Supplement, Low Dose</title>
            <description>25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O2">
            <title>LCPUFA Oil Supplement, Medium Dose</title>
            <description>50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O3">
            <title>LCPUFA Oil Supplement, High Dose</title>
            <description>75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
          </group>
          <group group_id="O4">
            <title>Canola Oil</title>
            <description>Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days&#xD;
Canola Oil Placebo: Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Biological Signatures</title>
          <description>Changes in the biological signatures (IL-1β, IL-2, IFNγ) from baseline to the end of the trial.</description>
          <population>11 participants were not included in analysis due to missing a scheduled blood draw at 90 days post randomization.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1β</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.64"/>
                    <measurement group_id="O2" value="-0.02" spread="0.38"/>
                    <measurement group_id="O3" value="-0.03" spread="0.16"/>
                    <measurement group_id="O4" value="0.11" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.34"/>
                    <measurement group_id="O2" value="-0.29" spread="0.01"/>
                    <measurement group_id="O3" value="-0.11" spread="0.26"/>
                    <measurement group_id="O4" value="0.01" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNγ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" spread="0.67"/>
                    <measurement group_id="O2" value="-1.43" spread="0.56"/>
                    <measurement group_id="O3" value="2.99" spread="0.19"/>
                    <measurement group_id="O4" value="-9.77" spread="43.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 90 days post-randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LCPUFA Oil Supplement, Low Dose</title>
          <description>25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="E2">
          <title>LCPUFA Oil Supplement, Medium Dose</title>
          <description>50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="E3">
          <title>LCPUFA Oil Supplement, High Dose</title>
          <description>75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days&#xD;
LCPUFA Oil Supplement: 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
        </group>
        <group group_id="E4">
          <title>Canola Oil</title>
          <description>Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days&#xD;
Canola Oil Placebo: Equal volume of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear</sub_title>
                <description>Includes ear infection, poor hearing, and fluid in ears.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <description>Includes eye irritation and conjunctivitis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>Includes changes in appetite, constipation, diarrhea, stomach pain/discomfort, changes in frequency of bowel movements, flatulence, heartburn, changes in stool color/consistency, vomiting, and gastrointestinal virus.</description>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E3" events="30" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E4" events="38" subjects_affected="22" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious</sub_title>
                <description>Includes common cold, fever, feeling flushed/warm, flu, and hand, foot and mouth.</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E4" events="21" subjects_affected="19" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Injury</sub_title>
                <description>Includes head injury, chin laceration, etc.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular</sub_title>
                <description>Includes muscle, joint and bone pain, head shaking, clumsiness, improved motor skills, and tics.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Mouth</sub_title>
                <description>Includes teething and jaw pain.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Energy</sub_title>
                <description>Includes overly excited or energetic, calmness, and fatigue.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sleep</sub_title>
                <description>Includes difficulty falling asleep, interrupted sleep, nightmares, drowsiness, and sleeping too much.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <description>Includes anxiety, aggression, increase in negative behaviors/emotions, confusion/slowed thinking, irritability, changes with speech, better memory, and understanding more.</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E4" events="17" subjects_affected="12" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genital</sub_title>
                <description>Includes diurnal enuresis and improved toilet training.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nose</sub_title>
                <description>Includes nasal/sinus congestion, runny nose, sore throat, strep throat, and tonsillectomy.</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Chest</sub_title>
                <description>Includes allergies, bronchitis, cold symptoms, coughing, and upper respiratory infection.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were initially unanticipated obstacles in identifying enough patients because the ADOS scores were not consistently available for all patients in the electronic medical record system (EPIC), and this score served as part of the eligibility criteria. This problem was solved, and our recruitment pace rebounded, we went from approximately 2-3 enrollments per month to 6.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sarah Keim</name_or_title>
      <organization>Nationwide Children's Hospital</organization>
      <phone>1-800-792-8401 ext 52849</phone>
      <email>sarah.keim@nationwidechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

